Novavax (NVAX) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Novavax Revenue Highlights

Latest Revenue (Y)

$682.16M

Latest Revenue (Q)

$88.31M

Main Segment (Y)

Licensing, Royalties, and Other

Main Geography (Y)

UNITED STATES

Novavax Revenue by Period

Novavax Revenue by Year

Date	Revenue	Change
2024-12-31	$682.16M	22.61%
2023-12-31	$556.38M	-65.20%
2022-12-31	$1.60B	39.49%
2021-12-31	$1.15B	141.02%
2020-12-31	$475.60M	2448.48%
2019-12-31	$18.66M	-45.57%
2018-12-31	$34.29M	9.98%
2017-12-31	$31.18M	103.06%
2016-12-31	$15.35M	-57.65%
2015-12-31	$36.25M	18.24%
2014-12-31	$30.66M	46.59%
2013-12-31	$20.91M	-5.26%
2012-12-31	$22.08M	50.30%
2011-12-31	$14.69M	4182.22%
2010-12-31	$343.00K	5.54%
2009-12-31	$325.00K	-69.45%
2008-12-31	$1.06M	-29.68%
2007-12-31	$1.51M	-67.69%
2006-12-31	$4.68M	-36.61%
2005-12-31	$7.39M	-10.56%
2004-12-31	$8.26M	-29.91%
2003-12-31	$11.79M	-21.46%
2002-12-31	$15.01M	-37.65%
2001-12-31	$24.07M	872.36%
2000-12-31	$2.48M	106.25%
1999-12-31	$1.20M	71.43%
1998-12-31	$700.00K	40.00%
1997-12-31	$500.00K	400.00%
1996-12-31	$100.00K	-

Novavax generated $682.16M in revenue during NA 2024, up 22.61% compared to the previous quarter, and up 3655.35% compared to the same period a year ago.

Novavax Revenue by Quarter

Date	Revenue	Change
2024-12-31	$88.31M	4.50%
2024-09-30	$84.51M	-79.66%
2024-06-30	$415.48M	342.69%
2024-03-31	$93.86M	-67.79%
2023-12-31	$291.34M	1220.44%
2023-09-30	$22.06M	-94.80%
2023-06-30	$424.43M	424.30%
2023-03-31	$80.95M	-71.88%
2022-12-31	$287.83M	-60.82%
2022-09-30	$734.58M	295.09%
2022-06-30	$185.93M	-73.59%
2022-03-31	$703.97M	216.82%
2021-12-31	$222.20M	24.24%
2021-09-30	$178.84M	-39.99%
2021-06-30	$298.02M	-33.36%
2021-03-31	$447.23M	59.92%
2020-12-31	$279.66M	78.10%
2020-09-30	$157.02M	341.85%
2020-06-30	$35.54M	952.35%
2020-03-31	$3.38M	-61.69%
2019-12-31	$8.82M	251.66%
2019-09-30	$2.51M	-25.32%
2019-06-30	$3.36M	-15.70%
2019-03-31	$3.98M	-35.01%
2018-12-31	$6.13M	-20.79%
2018-09-30	$7.74M	-28.20%
2018-06-30	$10.77M	11.60%
2018-03-31	$9.65M	-7.29%
2017-12-31	$10.41M	24.66%
2017-09-30	$8.35M	24.06%
2017-06-30	$6.73M	18.52%
2017-03-31	$5.68M	5.20%
2016-12-31	$5.40M	67.10%
2016-09-30	$3.23M	28.98%
2016-06-30	$2.50M	-40.61%
2016-03-31	$4.22M	-27.93%
2015-12-31	$5.85M	-10.30%
2015-09-30	$6.53M	-53.38%
2015-06-30	$14.00M	41.70%
2015-03-31	$9.88M	46.89%
2014-12-31	$6.72M	-18.14%
2014-09-30	$8.21M	-0.54%
2014-06-30	$8.26M	10.68%
2014-03-31	$7.46M	-14.70%
2013-12-31	$8.75M	82.17%
2013-09-30	$4.80M	36.00%
2013-06-30	$3.53M	-7.88%
2013-03-31	$3.83M	-16.05%
2012-12-31	$4.57M	-20.80%
2012-09-30	$5.76M	-18.84%
2012-06-30	$7.10M	53.02%
2012-03-31	$4.64M	-20.58%
2011-12-31	$5.84M	16.71%
2011-09-30	$5.01M	66.88%
2011-06-30	$3.00M	259.83%
2011-03-31	$834.00K	1535.29%
2010-12-31	$51.00K	-70.86%
2010-09-30	$175.00K	2400.00%
2010-06-30	$7.00K	-93.64%
2010-03-31	$110.00K	48.65%
2009-12-31	$74.00K	-63.18%
2009-09-30	$201.00K	593.10%
2009-06-30	$29.00K	38.10%
2009-03-31	$21.00K	-70.00%
2008-12-31	$70.00K	-63.92%
2008-09-30	$194.00K	-43.27%
2008-06-30	$342.00K	-25.33%
2008-03-31	$458.00K	-172.81%
2007-12-31	$-629.00K	-

Novavax generated $88.31M in revenue during Q4 2024, up 4.50% compared to the previous quarter, and up 400.25% compared to the same period a year ago.

Novavax Revenue Breakdown

Novavax Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Product	$190.21M	$531.39M	-	-	-
Licensing, Royalties, and Other	$491.95M	-	-	-	-
Royalties and Other	-	$24.99M	$43.99M	$197.58M	-
Grant	-	$427.32M	$258.35M	-	-
Sales-Based Royalties	-	-	$9.00M	$178.60M	-
Government Contract	-	-	-	-	$217.25M

Novavax's latest annual revenue breakdown by segment (product or service), as of Dec 24: Licensing, Royalties, and Other (72.12%), and Product (27.88%).

Quarterly Revenue by Product

Product/Service	Mar 25	Dec 24	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Cost Reimbursements	$11.27M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Licensing, Royalties, and Other	$44.98M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product	-	$69.68M	$38.21M	$82.32M	$529.16M	$2.23M	$287.79M	$626.09M	$55.45M	$585.63M	-	-	-	-	-	-	-	-	-	-
License Fees	-	-	$9.90M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant	-	-	-	-	$37.94M	$164.92M	$137.08M	$87.38M	$105.66M	$35.54M	$3.38M	$1.32M	$2.51M	-	-	-	-	-	-	-
Royalties and Other	-	-	-	$11.53M	$1.95M	$19.83M	$2.18M	$1.03M	$39.00K	$2.21M	$22.70M	$19.04M	-	-	-	-	-	-	-	-
Sales-Based Royalties	-	-	-	-	-	-	-	-	$-1.50M	-	-	-	-	-	-	-	-	-	-	-
Royalty	-	-	-	-	-	-	-	-	-	-	-	-	$39.94M	$23.46M	-	-	-	-	-	-
Government Contract	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$140.00M	$1.62B	-	-	-	-

Novavax's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: Licensing, Royalties, and Other (79.97%), and Cost Reimbursements (20.03%).

Novavax Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 23	Dec 22
UNITED STATES	$522.53M	-	-
Europe	$96.14M	$268.36M	$823.54M
Rest of North America	$4.46M	-	-
Rest of the World	$59.02M	$233.07M	$536.94M
North America	-	$29.96M	$194.48M

Novavax's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (76.60%), Europe (14.09%), Rest of the World (8.65%), and Rest of North America (0.65%).

Quarterly Revenue by Country

Country	Mar 25	Dec 24	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23
Rest of the World	$43.29M	$57.68M	$3.07M	$-1.73M	$14.15M	-	$283.64M	$-64.72M
UNITED STATES	$39.41M	-	-	-	-	-	-	-
Europe	$8.09M	$4.56M	$1.17M	$90.42M	$209.58M	-	$1.52M	$57.27M
CANADA	$575.67M	-	-	-	-	-	-	-
North America	-	-	$33.97M	$-6.36M	$27.73M	$2.23M	-	-

Novavax's latest quarterly revenue breakdown by geography, as of Mar 25: CANADA (86.38%), Rest of the World (6.50%), UNITED STATES (5.91%), and Europe (1.21%).

Novavax Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
AZN	AstraZeneca	$45.81B	$12.68B
BNTX	BioNTech SE	$3.82B	$187.60M
MRNA	Moderna	$3.24B	$107.00M
NVAX	Novavax	$682.16M	$88.31M
VXRT	Vaxart	$28.70M	$15.19M
INO	Inovio Pharmaceuticals	-	$116.99K

NVAX Revenue FAQ

What is Novavax’s yearly revenue?

Novavax's yearly revenue for 2024 was $682.16M, representing an increase of 22.61% compared to 2023. The company's yearly revenue for 2023 was $556.38M, representing a decrease of -65.20% compared to 2022. NVAX's yearly revenue for 2022 was $1.6B, representing an increase of 39.49% compared to 2021.

What is Novavax’s quarterly revenue?

Novavax's quarterly revenue for Q4 2024 was $88.31M, a 4.50% increase from the previous quarter (Q3 2024), and a -69.69% decrease year-over-year (Q4 2023). The company's quarterly revenue for Q3 2024 was $84.51M, a -79.66% decrease from the previous quarter (Q2 2024), and a 283.03% increase year-over-year (Q3 2023). NVAX's quarterly revenue for Q2 2024 was $415.48M, a 342.69% increase from the previous quarter (Q1 2024), and a -2.11% decrease year-over-year (Q2 2023).

What is Novavax’s revenue growth rate?

Novavax's revenue growth rate for the last 3 years (2022-2024) was -57.34%, and for the last 5 years (2020-2024) was 43.43%.

What are Novavax’s revenue streams?

Novavax's revenue streams in c 24 are Product, and Licensing, Royalties, and Other. Product generated $190.21M in revenue, accounting 27.88% of the company's total revenue, down -64.20% year-over-year. Licensing, Royalties, and Other generated $491.95M in revenue, accounting 72.12% of the company's total revenue

What is Novavax’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Novavax was Licensing, Royalties, and Other. This segment made a revenue of $491.95M, representing 72.12% of the company's total revenue.